CA-LIGHTBITS-LABS
Lightbits Labs today announced advancements to its cloud-native storage solution, enabling customers to confidently scale their private, hybrid, and edge cloud deployments. Lightbits, recently backed by Intel Capital , has extended its solution’s capabilities with the delivery of LightOS™ 2.1. This release further enhances high-performance, scalability, and low latency. Today’s news underpins the Lightbits vision of enabling organizations to unleash hyperscale storage for private clouds, but at a fraction of the cost of even the most advanced cloud storage offerings. LightOS 2.1 further enhances QoS for logical volumes during drive failure recoveries, multi-tenancy capabilities and adds directed-availability of snapshots and thin clones.
The new age of 5G, IoT, AI and ML and ever-increasing analytic data, calls for cloud-optimized block storage volumes that support higher IOPS, higher bandwidth and sub-millisecond, low-variance I/O latency. Like the Amazon EBS io2 Block Express volumes , which was recently announced at the AWS Re:Invent conference, Lightbits Labs’ LightOS provides high-performance, low-latency block storage volumes for on-prem cloud native application environments.
“Lightbits realized early on that disaggregated, high-performance software defined storage that utilized standard Ethernet networking is what would drive successful on-premises cloud deployments,” said Avigdor Willenz, co-founder and chairman of Lightbits Labs and previously co-founder of Annapurna Labs, acquired by Amazon in 2015. “The new Amazon EBS io2 Block Express volumes utilize scalable reliable datagrams that are implemented using custom-built, dedicated hardware. We specifically developed LightOS and NVMe/TCP to avoid the need for special network hardware yet provide a level of performance similar to local NVMe.”
As AWS extends its infrastructure offerings to hybrid cloud with its Outpost offerings, it’s clear that the future of scalable infrastructure is in native cloud practices regardless of where cloud is deployed. For private, hybrid and edge cloud deployments, Lightbits’ LightOS delivers the same or better performance than the latest Amazon EBS io2 Block Express volumes at lower cost. “This enables us to bring high-performance infrastructure for all data centers with our key Intel product portfolio,” said Remi El-Ouazzane, Vice President and Data Platforms Group Chief Strategy and Business Development Officer at Intel. “Given our recent partnership with Lightbits, we’ve had strong customer momentum in the space of disaggregated storage over TCP with customers deploying the solution in production on bare metal edge, enterprise private cloud (financial), and multi-tenancy Kubernetes-based environment for cloud service providers.”
LightOS scale out disaggregated storage solution is perfect for the largest, most performance-sensitive cloud native applications with improved price-performance, ease-of-implementation, availability and scalability. Further, as AWS is now announcing with EBS Gp3 volumes, LightOS has always decoupled IOPS from storage capacity and allowed for independent scaling of storage and compute. When combining this level of performance and flexibility along with other standard features such as thin provisioning, compression, snapshots and thin clones and the ability to utilize and extend the endurance of any flash, including QLC SSDs, it delivers EBS-like “Hyperscale Storage for All” for enterprise private clouds.
Intel’s Remi El-Ouazzane further states: “Our work with Lightbits to optimize the joint solution around Intel® Xeon® Scalable Processors, Optane™ Persistent Memory, 3D NAND QLC SSDs, and Intel® Ethernet 800 Series network adapters has delivered improved performance and TCO for our customer ecosystem.”
LightOS 2.1 is available immediately and offers better performance, scalability and latency than the most advanced cloud offerings for private clouds. With a fully programmatic API, and integration with Kubernetes and OpenStack, and the choice of software-only or a fully integrated and ready-to-run appliance, Lightbits Labs’ LightOS is ready to unleash the full power of private, hybrid and edge clouds for the next 10 years of cloud architecture.
Lightbits Labs Resources
- IDC Research: NVMe/TCP Enables the Democratization of Disaggregated NVMe-based Storage
- Lightbits Labs Hyperscale Storage for All Video
- LightOS 2.0 Product Overview: Software-Defined Composable Storage
- Kubernetes and LightOS: Performance, Persistence, Simplicity
- Apache Kafka and LightOS
About Lightbits Labs™
Lightbits Labs “Hyperscale Storage for All” delivers composable NVMe/TCP storage that enables on-premise, hybrid cloud, and cloud native environments to independently scale storage from compute thereby unleashing hyperscale flexibility while lowering cost and performing like local flash. The highly available software-defined storage maximizes utilization, helping customers maintain operational efficiency and easily scale their business.
Founded in 2016, Lightbits pioneered NVMe/TCP and delivered the industry’s first NVMe/TCP storage solution. Lightbits is backed by strategic investors including Intel Capital, Dell Technologies Capital, Cisco Investments, and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com .
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom